Pharma: Page 2


  • Katelyn Jetelina
    Image attribution tooltip
    Permission granted by Katelyn Jetelina
    Image attribution tooltip
    Q&A

    ‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.

    Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.

    By Alexandra Pecci • Oct. 9, 2024
  • Futuristic medicine research gene therapy health analysis vector illustration.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As AI transforms drug development, biotechs might not need as much Big Pharma support

    Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.

    By Oct. 9, 2024
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Boxes bearing the brand name Wegovy are arranged on a table.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds

    Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.

    By Kelly Bilodeau • Oct. 7, 2024
  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    Flu vaccination rates are falling despite record child deaths. Can innovation save the day?

    As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help.

    By Oct. 3, 2024
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How Roche plans to fill a projected $8B sales gap

    Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.

    By Oct. 2, 2024
  • business executives mingling in a conference building
    Image attribution tooltip
    hxdbzxy via Getty Images
    Image attribution tooltip

    Top pharma and biotech conferences 2025

    Mark your calendars for the most important industry conferences in 2025.

    By Oct. 1, 2024
  • Joe Panetta
    Image attribution tooltip
    Permission granted by Biocom
    Image attribution tooltip
    Q&A

    California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.

    The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.

    By Alexandra Pecci • Oct. 1, 2024
  • Preparing machine for work in pharmaceutical factory.
    Image attribution tooltip
    RGtimeline via Getty Images
    Image attribution tooltip
    Sponsored by Hexagon

    Why today’s leading pharma manufacturers are adopting proactive asset management strategies

    In recent months, high-profile drug shortages have brought pharmaceutical manufacturing operations into the spotlight.

    Sept. 30, 2024
  • studying brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades

    The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.

    By Kelly Bilodeau • Sept. 26, 2024
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip
    Q&A

    Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

    Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.

    By Sept. 26, 2024
  • eye dna helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Fresh data intensifies race for a major gene therapy target

    4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.

    By Sept. 25, 2024
  • Alicia Zhou, CEO, Cancer Research Institute
    Image attribution tooltip
    Permission granted by CRI
    Image attribution tooltip
    Q&A // First 90 Days

    Want better cancer treatments? Make biopharma more like Silicon Valley

    Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.

    By Sept. 24, 2024
  • world map pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up

    A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.

    By Alexandra Pecci • Sept. 23, 2024
  • Federal Reserve chairman Jerome Powell speaks at a news conference on Sept. 18, 2024.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    What the Fed’s rate cut means for biotech

    Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

    By Ben Fidler • Sept. 20, 2024
  • Meg Alexander headshot
    Image attribution tooltip
    Permission granted by Ovid Therapeutics
    Image attribution tooltip

    After epilepsy setback, Ovid charges confidently ahead in CNS

    A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.

    By Sept. 20, 2024
  • Scientist suit handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    At J&J, oncology R&D meets commercial strategy in a quest for new standards of care

    The disparate teams of research and commercial at J&J work closely together from the get-go.

    By Sept. 19, 2024
  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Getting IND ready — how companies can avoid common traps

    Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.

    By Alexandra Pecci • Sept. 18, 2024
  • blue World Map on digital pixelated display
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA inspection backlog overseas threatens new drug approvals

    The FDA’s backlog of overseas drug manufacturer inspections is still mounting — and new drugs could be delayed as a result.

    By Sept. 18, 2024
  • Radiopharmaceutical
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How a radiopharma up-and-comer builds momentum in a surging space

    Big Pharma is embracing the radiopharmaceuticals boom that was a long time in the making.

    By Sept. 17, 2024
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biopharma prepares to pivot from China as Biosecure Act advances

    After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be  forced to cut ties with five Chinese contract partners.

    By Sept. 16, 2024
  • brain scan
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The hunt for game-changers against the deadliest form of brain cancer

    Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.

    By Kelly Bilodeau • Sept. 16, 2024
  • Lilly Biotechnology Center in San Diego, California
    Image attribution tooltip
    Michael Vi / Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    How Lilly’s sustainability goals come face to face with massive growth

    Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.

    By Sept. 12, 2024
  • Sanofi and Regeneron's Dupixent
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    3 FDA approval dates to watch in the year’s final push

    A handful of potential blockbusters are marching toward FDA review.

    By Sept. 11, 2024
  • Charlotte Owens
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip

    Why pharma should redefine ‘women’s health’

    A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon. 

    By Alexandra Pecci • Sept. 11, 2024
  • Pharmaceutical cartons with the logo for Bristol Myers Squibb's Opdivo rest on a refrigerator shelf.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Deep Dive

    A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

    Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

    By Jonathan Gardner • Sept. 10, 2024